Shionogi Expects Crestor To Overtake Pfizer’s Lipitor
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Shionogi & Co. of Osaka is projecting domestic sales of its cholesterol treatment Crestor (rosuvastatin) to grow 82 percent in fiscal 2008 to ¥19 billion ($180 million), thanks to its lower price and additional efficacy compared to competitor Pfizer's Lipitor (atorvastatin), a company official said July 2
You may also be interested in...
Shionogi’s Brisk Crestor Sales Help It Buck Industry Tide Of Lower Earnings
TOKYO - Bolstered by strong global sales of its blockbuster cholesterol agent Crestor, marketed by AstraZeneca, Shionogi forecast Nov. 5 that it expected a 20 percent profit jump for the full business year ending next March. The company stands out among leading Japanese drug makers for reporting income gains for both the full year and half-year ended in September
Shionogi’s Brisk Crestor Sales Help It Buck Industry Tide Of Lower Earnings
TOKYO - Bolstered by strong global sales of its blockbuster cholesterol agent Crestor, marketed by AstraZeneca, Shionogi forecast Nov. 5 that it expected a 20 percent profit jump for the full business year ending next March. The company stands out among leading Japanese drug makers for reporting income gains for both the full year and half-year ended in September
Shionogi Shifts Sales Focus To Crestor
Japan's Shionogi plans to step up its promotions in hospitals to create an 83 percent increase in domestic sales of its Crestor (rosuvastatin) cholesterol drug by next March. The company said it would train some of its 1,450 medical representatives to promote use of the drug in hospitals instead of only to clinics, and to track the frequency with which it is prescribed. The focus on the statin marks a shift by Shionogi away from anti-microbial agents and their declining sales to metabolic syndrome medicines. (Click here for more - a subscription may be required